GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025

AI Briefing

• – GenSight Biologics reports estimated full-year consolidated financial results for 2025, a biopharma company focused on developing and commercializing innovative gene therapies, estimated results will be reviewed by the Audit Committee and Board of Directors on March 25, 2026.
• – The company is focused on retinal neurodegenerative diseases and central nervous system disorders.
• – Final accounts to be approved by the Board of Directors